This post was authored by Lisa Egbuonu-Davis, M.D., Vice President, Global Patient Centered Outcomes & Solutions, who, in honor of Black History Month, shares her story about why she is committed to supporting gifted students from underrepresented minorities and socioeconomic disadvantaged groups. Lisa is a graduate of the Johns Hopkins School of Medicine and Bloomberg […]VIEW FULL POST
For full financial data and non-GAAP reconciliations, please refer to Sanofi’s 2016 Annual Results and Presentation issued February 8, 2017, available at http://en.sanofi.com/investors/investors.aspx.
More information is also available via the press release.
Author: Kristin Schuhwerk, VP, Global Head of Clinical Operations, Sanofi
This past November, my colleague Paul Deutsch shared some valuable information about Phase 1 clinical trials, as part of our Drug Development 101 series. Today, I’d like to build on this information by providing some insight on what comes after Phase 1 clinical trials – Phase […]
For this edition of Sanofi Stories, we connected with Kalahn Taylor-Clark, US Head of Public Affairs in the Cardiovascular Business Unit at Sanofi US, who was recently appointed to the Board of Trustees at her alma mater Tufts University. Read on to learn more about the changes she is seeing in providing support – both […]VIEW FULL POST